Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
about
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): structured literature review and physician insightsAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmAn observation of prescription behaviors and adherence to guidelines in patients with COPD: real world data from October 2012 to September 2014.Use of electronic medical records and biomarkers to manage risk and resource efficienciesDeterminants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia.Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.Inhalational Steroids and Iatrogenic Cushing's SyndromeDiagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Bufei Yishen granule combined with acupoint sticking improves pulmonary function and morphormetry in chronic obstructive pulmonary disease ratsThe effects of corticosteroids on COPD lung macrophages: a pooled analysisThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practiceCurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon.Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.COPD: early diagnosis and treatment to slow disease progression.Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease.Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?Skeletal Implications of Chronic Obstructive Pulmonary Disease.Attenuation of Cigarette Smoke-Induced Emphysema in Mice by Apolipoprotein A-1 Overexpression.Convergence in the Epidemiology and Pathogenesis of COPD and Pneumonia.Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.This patient is not breathing properly: is this COPD, heart failure, or neither?Optimizing bronchodilation in the prevention of COPD exacerbationsFactors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain).Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease.Long-Acting Bronchodilator Use in the Management of Stable COPD: A Review.Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Triple Therapy in COPD: What We Know and What We Don't.
P2860
Q26801661-B55F9370-2A3E-4E88-877C-28E9ED937122Q27348844-EFCD4F3E-E894-4811-8702-E63977ABF0A5Q28068805-5BB8F96C-7FC1-4313-A4B7-A2C5E2D6951AQ28074169-A964781C-3DB6-4E03-BDD6-A91224D4EEE6Q28087788-AA187458-4484-4219-A922-6B0FE0A9CA5BQ31100125-50711EC9-E5CF-4F70-BC22-0A7DF5217310Q33602020-D358248D-3D01-4E3D-BD9F-13491A581B2FQ33854276-68DBC0C5-C436-41C7-AE7C-70ED412C239FQ33933904-70EAE43D-81B6-4DF4-8CF0-84C0AAB043E3Q34003435-8F7A5FFE-68B3-407E-BD20-E932B3BCA98AQ34134884-03CC7CFE-61AB-4C45-9B6C-F0C7018687F1Q35056151-60F73DF9-7D77-4704-8D5B-77E3CD157B81Q35538249-AC0CA1DE-66D1-4AD9-8206-A1E322388413Q35740245-22504482-BA76-4732-980B-D727406DA087Q35985973-357B9E6A-A93B-4F20-83BA-FCEB6B197330Q36208427-F00F0182-5063-463E-8386-54FBC7D870E3Q36302882-E2DF767A-DCD6-432B-BD8C-941E8032A07EQ36332206-74230B6C-1E9D-49BE-A8B3-C72CD8663C20Q36907742-1E301063-148B-409D-811E-67871708AB52Q37283438-5437E4C8-7000-4EE1-92FA-07DB30B94C12Q37390146-3D9685C4-A169-4A91-9CF2-B3C4E7C35D65Q37614103-75DEE1CD-4536-456B-A076-B104CD76C036Q37741110-DC3E8E2D-305D-447A-AD6C-0AA6D73F3C11Q38248535-3CC1030E-E226-44EF-B78D-4429AB1A0F3AQ38264345-1C9CA147-99F7-409C-B244-07F071DE3AD3Q38284373-536E2806-8F0D-4682-9D27-3784502F0810Q38306695-9DA535A0-B435-4510-906B-C7167F2C5709Q38571581-099EAEBB-E216-4B88-8B2D-B5AC38EFF6F5Q38727968-9D99D3B7-5675-476E-B2FD-EE456D12ECFCQ38862679-92CA1408-9C02-47A2-AF3D-2FB7D2A1CA0FQ38867042-5C5AA0DB-0E27-4C40-BBF2-4455530FEC8FQ39040871-08EB6342-EDC1-4AD8-9C31-10101CA956C1Q39232408-3B9CC576-B41E-4CBE-A42C-0C6AC5A24326Q39386571-CDCE425D-008A-44B1-B5E0-6D41B4A6BF7EQ39420903-7B058082-732C-4392-840F-35A95BB190AEQ47127219-09ECA22B-6C23-4992-81C6-1DC4716CAEBDQ47138049-5D4C1808-41ED-4E01-B3A6-F99652C6D0ACQ47282204-B945E7E6-1690-4CE9-9D1A-073218661A77Q47661714-FA98FF6C-B3D8-4A5D-9015-4386C3B9CA49Q48335044-4A993326-61DA-4D1B-B4ED-8ED18044AB65
P2860
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
@en
type
label
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
@en
prefLabel
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
@en
P2860
P356
P1476
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
@en
P2093
Andrea Rossi
Barbara Yawn
P2860
P2888
P304
P356
10.4104/PCRJ.2012.00092
P577
2013-03-01T00:00:00Z
P5875
P6179
1030177860